GlucoTrack Files IDE for Implantable Glucose Monitor

GlucoTrack ( (GCTK) ) has issued an announcement.

On May 7, 2026, Glucotrack announced that it has submitted an Investigational Device Exemption application to the U.S. Food and Drug Administration, seeking authorization to begin a U.S. clinical study of its fully implantable continuous blood glucose monitoring technology. The move follows several years of engineering, preclinical evaluation and iterative design work, marking a key transition from preclinical to clinical development in the United States for its long-term, blood-based monitoring platform.

The IDE filing, if cleared, would allow Glucotrack to generate clinical data needed to support future regulatory approvals for its discreet, long-duration implantable glucose sensor, which aims to eliminate on-body wearables and frequent sensor changes. This step is significant for the company’s strategy in the competitive diabetes technology market, potentially enhancing its positioning with a differentiated, “virtually invisible” device designed to improve convenience and quality of life for people with diabetes.

Spark’s Take on GCTK Stock

According to Spark, TipRanks’ AI Analyst, GCTK is a Neutral.

The score is primarily weighed down by weak financial performance (pre-revenue, large and persistent losses, and significant cash burn) and an unfavorable valuation signal (negative P/E with no dividend). Technicals remain broadly weak (below key longer-term moving averages with negative MACD), while recent corporate updates provide some offset via encouraging preclinical/regulatory progress, tempered by dilution/financing risk.

To see Spark’s full report on GCTK stock, click here.

More about GlucoTrack

Glucotrack, Inc. is a medical technology company focused on designing, developing and commercializing novel technologies for people with diabetes. The Nasdaq-listed company is currently developing a long-term, implantable continuous blood glucose monitoring system intended to measure blood glucose levels for up to three years with minimal calibration and no on-body wearable component.

Glucotrack’s Continuous Blood Glucose Monitor is an investigational, fully implantable system that continually tracks blood glucose via a blood-based sensor. The device is limited by U.S. law to investigational use at this stage, reflecting its current position in the clinical and regulatory development pathway rather than in commercial deployment.

Average Trading Volume: 4,593,244

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.66M

See more data about GCTK stock on TipRanks’ Stock Analysis page.